To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Read time: 1 mins
Last updated:4th Feb 2013
The primary objective of this study is to assess and compare the pharmacokinetics (PK) of Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day), SPIRIVA�, HandiHaler�, (18 mcg/day) and Respimat� Soft Mist� Inhaler (SMI) (5.0 mcg/day) following repeat dosing for 7 days in subjects with COPD.
|Study start date||2013-02-04|